SABCS 2025
Dec 9 - 12, 2025 | San Antonio, TX
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
Circulating Tumor DNA Biomarker Analyses of a Phase 1/2 Study Evaluating Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in ER+/HER2- Advanced Breast CancerS Wander et al.
Poster
Real-world Prevalence of ESR1 Mutations Among Patients With ER+/HER2- Metastatic Breast Cancer After First-line Treatment With Endocrine Therapy and/or a CDK4/6 InhibitorD Chandiwana et al.
Poster
Subgroup Analyses of VERITAC-2: A Phase 3 Trial of Vepdegestrant, a PROTAC ER Degrader, vs Fulvestrant in ER+/HER2- Advanced Breast CancerE Hamilton et al.